Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes. 2011;4(3):276-282. 77. Schaefer C, Wuillemin WA, Kessels A, Jacobson A, Nagler M. Predictors of anticoagulation quality in 15 834 patients performing patient self- management of oral anticoagulation with vitamin K antagonists in real-life practice: a survey of the International Self-Monitoring Association of Orally Anticoagulated Patients. Br J Haematol. 2016;175(4):677-685. 78. Tosetto A, Manotti C, Marongiu F; Italian Federation of Anticoagulation Clinics (FCSA) Clinical Quality Study Group. Center-related determinants of VKA anticoagulation quality: a prospective, multicenter evaluation. PLoS One. 2015;10(12):e0144314. 79. Pengo V, Barbero F, Biasiolo A, Pegoraro C, Cucchini U, Iliceto S. A comparison between six- and four-week intervals in surveillance of oral anticoagulant treatment. Am J Clin Pathol. 2003;120(6):944-947. 80. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med. 2011;155(10):653-659. 81. Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation. 2014; 129(13):1407-1414. 82. Lidstone V, Janes S, Stross P. INR: intervals of measurement can safely extend to 14 weeks. Clin Lab Haematol. 2000;22(5):291-293. 83. Shalev V, Rogowski O, Shimron O, et al. The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation. Thromb Res. 2007;120(2):201-206. 84. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144(9):673-684. 85. Leizorovicz A, Siguret V, Mottier D, et al; Innohep in Renal Insufficiency Study Steering Committee. 